|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong J, Li B, Lin D, Zhou Q and Huang D:
Advances in targeted therapy and immunotherapy for non-small cell
lung cancer based on accurate molecular typing. Front Pharmacol.
10:2302019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bi X, Song P, Wang C, Zhang X and Liu C:
Genomic profiling reveals non-small cell lung cancer with common
mutations of EGFR exon 20 and exon 21: A case report. Transl Cancer
Res. 11:1423–1428. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
‘uncommon’ epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Azzoli CG, Baker S Jr, Temin S, Pao W,
Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et
al: American Society of Clinical Oncology clinical practice
guideline update on chemotherapy for stage IV non-small-cell lung
cancer. J Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beau-Faller M, Prim N, Ruppert AM,
Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet
JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in
non-small-cell lung cancer on 10 117 patients: A multicentre
observational study by the French ERMETIC-IFCT network. Ann Oncol.
25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Won YW, Han JY, Lee G, Park SY, Lim KY,
Yoon KA, Yun T, Kim HT and Lee JS: Comparison of clinical outcome
of patients with non-small-cell lung cancer harbouring epidermal
growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol.
64:947–952. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qin BD, Jiao XD, Yuan LY, Liu K, Wang Z,
Qin WX and Zang YS: The effectiveness of afatinib and osimertinib
in a Chinese patient with advanced lung adenocarcinoma harboring a
rare triple EGFR mutation (R670W/H835L/L833V): A case report and
literature review. Onco Targets Ther. 10:4739–4745. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li K, Yang M, Liang N and Li S:
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR
mutations in non-small cell lung cancer: Perplexity and solution
(Review). Oncol Rep. 37:1347–1358. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T,
Zhan P and Song Y: Treatment of uncommon EGFR mutations in
non-small cell lung cancer: New evidence and treatment. Transl Lung
Cancer Res. 8:302–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang YS, Tu SJ, Chen YC, Liu TY, Lee YT,
Yen JC, Fang HY and Chang JG: Mutation profile of non-small cell
lung cancer revealed by next generation sequencing. Respir Res.
22:32021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goel S, Bergholz JS and Zhao JJ: Targeting
CDK4 and CDK6 in cancer. Nat Rev Cancer. 22:356–372. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong W, Wang L, Zheng Z, Chen W, Du P and
Zhao H: Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic
biomarker for early non-small cell lung cancer. Transl Cancer Res.
9:95–103. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Wu Y, Wang X, Xu C, Wang L, Jian
J, Wu D and Wu G: CDK6 is upregulated and may be a potential
therapeutic target in enzalutamide-resistant castration-resistant
prostate cancer. Eur J Med Res. 27:1052022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sitthideatphaiboon P, Teerapakpinyo C,
Korphaisarn K, Leelayuwatanakul N, Pornpatrananrak N, Poungvarin N,
Chantranuwat P, Shuangshoti S, Aporntewan C, Chintanapakdee W, et
al: Co-occurrence CDK4/6 amplification serves as biomarkers of de
novo EGFR TKI resistance in sensitizing EGFR mutation non-small
cell lung cancer. Sci Rep. 12:21672022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Børresen AL, Andersen TI, Eyfjörd JE,
Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C,
Scherneck S, Hartman S, et al: TP53 mutations and breast cancer
prognosis: particularly poor survival rates for cases with
mutations in the zinc-binding domains. Genes Chromosomes Cancer.
14:71–75. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S,
Xu J, Feng J and Liu B: TP53 mutation is associated with a poor
clinical outcome for non-small cell lung cancer: Evidence from a
meta-analysis. Mol Clin Oncol. 5:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
González-Aguilera JJ, Oliart S, Azcoita MM
and Fernández-Peralta AM: Simultaneous mutations in K-ras and TP53
are indicative of poor prognosis in sporadic colorectal cancer. Am
J Clin Oncol. 27:39–45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Canale M, Petracci E, Delmonte A, Bronte
G, Chiadini E, Ludovini V, Dubini A, Papi M, Baglivo S, De Luigi N,
et al: Concomitant TP53 mutation confers worse prognosis in
EGFR-mutated non-small cell lung cancer patients treated with TKIs.
J Clin Med. 9:10472020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang YF and Liu PC: Afatinib and
osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS
mutation: A case report. Thorac Cancer. 12:3429–3432. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shan CG, Wang H, Lin T, Liu D, Wen L, Chen
ZJ, Zhen JJ, Lai MY, Zhang L, Zou X, et al: A non-small cell lung
cancer (NSCLC) patient with leptomeningeal metastasis harboring
rare epidermal growth factor receptor (EGFR) mutations G719S and
L861Q benefited from doubling dosage of osimertinib: A case report.
Ann Palliat Med. 10:5897–5901. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho JH, Lim SH, An HJ, Kim KH, Park KU,
Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, et al: Osimertinib for
patients with non-small-cell lung cancer harboring uncommon EGFR
mutations: A multicenter, open-label, phase II trial
(KCSG-LU15-09). J Clin Oncol. 38:488–495. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kobayashi S, Canepa HM, Bailey AS,
Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB:
Compound EGFR mutations and response to EGFR tyrosine kinase
inhibitors. J Thorac Oncol. 8:45–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grolleau E, Haddad V, Boissière L,
Falchero L and Arpin D: Clinical efficacy of osimertinib in a
patient presenting a double EGFR L747S and G719C mutation. J Thorac
Oncol. 14:e151–e153. 2019. View Article : Google Scholar : PubMed/NCBI
|
